Vidara Therapeutics
We are a specialty pharmaceutical company intent on utilizing our proven business model of creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management.
In June 2012 we acquired Actimmune (Interferon Gamma) our first product acquisition. Actimmune is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease and delaying time to disease progression in patients with Severe, Malignant Osteopetrosis.
We are seeking to acquire both commercial and late stage specialty niche therapeutics.
Vidara is a fully financed and profitable specialty pharmaceutical company.
Mr Rick McElheny
VP Business Development and Sales Operations
Viscadia Inc.
Viscadia is an analytically-driven management consulting firm that partners with companies in specialty pharmaceutical markets. Viscadia identifies and evaluates development, acquisition, licensing and life-cycle management opportunities. Additionally, Viscadia analyzes and optimizes the execution of specialty pharmaceutical commercial strategies. Viscadia is headquartered in San Diego, CA with a regional office in St. Louis, MO. For more information about Viscadia, email info@viscadia.com, call +1 858 496 7500 or visit www.viscadia.com.